Regeneron (NASDAQ: REGN) recorded $23.72 EPS in the fourth quarter, which topped the $18.37 analyst estimates by $5.35. In addition, the company reported $4.95 billion in revenue in the same quarter, which also beat the $4.42 billion analyst estimates.
Regeneron beats Q4 consensus earnings estimates.
Regeneron recorded a 104% increase in fourth-quarter revenue of about $4.95 billion, including a sum of $2.3 billion attributed to REGEN-COV. Full-year revenue for 2021 came to around $16.07 billion, representing a 89% increase. Net sales in the fourth quarter came to $1.55 billion, representing a 15% increase. Full-year net sales grew by 17%.
Regeneron’s Chief Executive Officer and President Leonard Schleifer M.D., Ph.D., said:
In 2021, Regeneron delivered strong results across our core business with impressive EYLEA and Dupixent growth, while also helping address the ongoing pandemic by delivering REGEN-COV to millions of patients
The CEO continued to say, For 2022, we remain focused on building on EYLEA’s success, expanding approvals and patient reach for Dupixent, pursuing new indications for Libtayo, and reading out data from our oncology pipeline – all while continuing to progress our diversified earlier-stage pipeline.
We also remain committed to our efforts to fight the COVID-19 pandemic and address the significant need for effective treatments and preventative approaches to SARS-CoV-2.
The CEO claimed they’re working hard to successfully create next-gen antibodies that battle Omicron and other variants, showing how REGEN-COV isn’t effective against the Omicron variant.
Business highlights
Regeneron has more than thirty product candidates undergoing clinical trials and studies, including a few marketed products being investigated for additional indications. Updates from these clinical pipelines
The FDA approved Dupixent and gave it the green light to treat kids
